Matrone Antonio, Citro Fabrizia, Gambale Carla, Prete Alessandro, Minaldi Elisa, Ciampi Raffaele, Ramone Teresa, Materazzi Gabriele, Torregrossa Liborio, Elisei Rossella
Unit of Endocrinology, Department of Clinical and Experimental Medicine, Pisa University Hospital, 56124 Pisa, Italy.
Endocrine Surgery Unit, Department of Surgical, Medical, Molecular Pathology and Critical Area, Pisa University Hospital, 56126 Pisa, Italy.
J Clin Med. 2023 Nov 7;12(22):6970. doi: 10.3390/jcm12226970.
Thyroid carcinoma (TC) is the most common endocrine cancer, with papillary thyroid carcinoma (PTC) being the most common subtype. BRAF and RAS oncogene were characterized as the most frequently altered genes in PTC, with a strong association between genotype and histotype. The most common mutation in BRAF gene is V600E and is prevalent in classic and aggressive variants of PTC, while BRAF K601E mutation is the most common among the other rare BRAF mutations. BRAF K601E mutated thyroid carcinomas are usually characterized by low aggressiveness, except for anecdotal cases of poorly differentiated TC.
We described a case of oncocytic carcinoma of the thyroid (OCA) with an aggressive clinical course, including widespread metastasis and resistance to radioiodine treatment. Molecular analysis revealed the exclusive presence of the BRAF K601E mutation in both primary tumor and metastatic lesions. Accordingly, a revision of the literature about aggressive TC cases carrying BRAF K601E mutation was performed.
Although rare, this case emphasizes the relevance of considering BRAF K601E mutation in advanced non-PTC thyroid carcinomas, since it can be considered an actionable mutation for target therapies.
甲状腺癌(TC)是最常见的内分泌癌,其中乳头状甲状腺癌(PTC)是最常见的亚型。BRAF和RAS癌基因被认为是PTC中最常发生改变的基因,其基因型与组织类型之间存在密切关联。BRAF基因最常见的突变是V600E,在PTC的经典型和侵袭性变体中普遍存在,而BRAF K601E突变是其他罕见BRAF突变中最常见的。BRAF K601E突变的甲状腺癌通常具有低侵袭性,但也有少数低分化TC的病例报道。
我们描述了一例甲状腺嗜酸细胞癌(OCA),其临床病程具有侵袭性,包括广泛转移和对放射性碘治疗耐药。分子分析显示,原发肿瘤和转移灶中均仅存在BRAF K601E突变。因此,我们对携带BRAF K601E突变的侵袭性TC病例的文献进行了回顾。
尽管罕见,但该病例强调了在晚期非PTC甲状腺癌中考虑BRAF K601E突变的重要性,因为它可被视为靶向治疗的一个可操作的突变。